Table 1 Summary of patient and tumor characteristics
Patient | Tissue | Diagnosis | ER(%)/PR(%)/HER2( +) | PAM50 Subtype | TIS Status | Treatment at the time of sample collection |
|---|---|---|---|---|---|---|
1 | Breast | IDC, DCIS | 2/0/3 | Luminal A | High | Gemcitabine and trastuzumab |
1 | Breast | Tumor emboli | N/A | Luminal A | High | Nab-paclitaxel and trastuzumab |
1 | Lung | Metastatic | 0/0/3 | HER2 enriched | High | Nab-paclitaxel and trastuzumab |
2 | Breast | ICD, DCIS | 0/0/3 | HER2 enriched | Low | None. Initial diagnosis |
2 | Breast | Residual IDC | 0/0/N/A | HER2 enriched | High | TDM1, pertuzumab, doxorubicin and cyclophosphamide* |
2 | Soft tissue | Local recurrence | 0/0/3 | HER2 enriched | Low | Trastuzumab and pertuzumab |
3 | Brain | Metastatic | 15/0/3 | HER2 enriched | Low | None. Discontinued due to toxicities |
4 | Breast | IDC | 0/0/3 | Basal like | High | None. Initial diagnosis |
4 | Breast | Local recurrence | N/A | Luminal A | High | Doxorubicin, cyclophosphamide, paclitaxel and trastuzumab |
5 | Brain | Metastatic | 0/0/3 | Basal like | Low | TDM1 and anastrozole |
6 | Breast | IDC, DCIS | 80/70/2** | Luminal A | High | None. Initial diagnosis |
7 | Breast | IDC, DCIS | 0/0/3 | HER2 enriched | High | None. Initial diagnosis |
7 | Breast | Local recurrence | N/A | Basal like | High | None. Completed neoadjuvant and adjuvant therapy |
8 | Breast | IDC, DCIS | 10/15/1 | Luminal A | Low | None. Initial diagnosis |
8 | Soft tissue | Local recurrence | 0/0/3 | Basal like | Low | Nab-paclitaxel and atezolizumab (previously had triple negative disease) |